Clinical Trials
12 trialsNCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03862157 2026-03-11
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03326310 2025-12-29
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
Phase 1 Recruiting
NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01290302 2025-06-12
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
Phase 1 Completed
NCT04866056 2022-12-01
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Terminated
NCT02587598 2021-12-08
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02129101 2019-10-30
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Phase 1 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT00569660 2012-08-07
Ph II Study of Azacitidine in Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00381693 2011-04-21
Azacitidine in Treating Patients With Myelofibrosis
Mayo Clinic
Phase 2 Terminated